logo
Plus   Neg
Share
Email

Eli Lilly Reports Data From Phase 2 SERENITY Study Evaluating Mirikizumab

Eli Lilly and Company (LLY) announced new efficacy and safety data from the phase 2 SERENITY study evaluating mirikizumab in patients with moderately to severely active Crohn's disease. The company said data from the 52-week study showed continued symptom improvement and reduction of intestinal mucosal inflammation. The company is presenting detailed results from the trial virtually in an abstract session at the UEG Week 2020.

The company said these phase 2 data reinforce the continued evaluation of mirikizumab in the ongoing, pivotal VIVID phase 3 program as a potential treatment for patients with Crohn's disease.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
After providing free and discounted rides to the polls on Election Day, Lyft is now set to support voters with discounted rides to the polls for the federal runoff races in Louisiana and Georgia. They also provided similar rides during the primary season. The ride-sharing company is continuing its Voting Access Program to provide affordable transportation to voters in need. Discount retailer Dollar General Corp. and supermarket chain Kroger Co. on Thursday reported sharp increases in their quarterly profits on higher sales. While Dollar General's results trounced analysts' estimates, Kroger's earnings beat expectations while revenue fell short. Dollar General's profit for the third quarter surged 57 percent from last year. On January 4, 2021, Discovery plans to launch its new standalone streaming service called Discovery+ which will also offer exclusive streaming access to the BBC's award-winning natural history shows like Planet Earth, Blue Planet, and Frozen Planet. The channel is expected to offer the largest content of real-life entertainment provided by any streaming platform at launch.
Follow RTT